Health Canada has approved Alemtuzumab. Alemtuzumab will be marketed by Genzyme as Lemtrada for the treatment of relapsing remitting multiple sclerosis (RRMS), with active disease, who have not shown an adequate response to interferon beta or other disease-modifying therapies. Alemtuzumab is a monoclonal antibody which targets the CD52 protein. The drug was used for several[…]
Health Canada Approves Alemtuzumab for RRMS Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Health Canada Approved 2013, Monoclonal Antibodies / mAb Tags: Alemtuzumabglatiramer acetateLemtradaleukemiarelapsing remitting multiple sclerosisRRMS Dec 13, 2013
Canada Approves Teriflunomide for Multiple Sclerosis
Anti-Inflammatory, Drug Research & Development API, FDA Approved 2012, Health Canada Approved 2013 Tags: multiple sclerosisrelapsing remitting multiple sclerosisRRMS Dec 06, 2013
On November 22, 2013 Health Canada approved the novel once daily pill Teriflunomide for the treatment of Multiple Sclerosis. Approved by the FDA in September of 2012, this efficacious drug is targeted for treating patients with relapsing remitting multiple sclerosis, or RRMS. The ease of use for this 14 milligram pill, taken only once a[…]
Canada Approves Simeprevir for Hepatitis C
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Priority Status, Health Canada Approved 2013 Tags: Hepatitis Cribavirin Dec 04, 2013
On November 20, 2013 Health Canada revealed the approval of Simeprevir, known as the brand name GALEXOS, to treat hepatitis C. Janssen, the company that markets GALEXOS offered excitement for the approval of it’s once a day hepatitis C treatment. Simeprevir is designed to be administered adjunctively with both ribavirin and pegylated interferon, for the[…]